Table 2. Univariate Cox regression analysis for OS and PFS in patients with OPSCC treated with CRT.
| Variables | OS | PFS | |||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | ||
| Sex | 0.91 | 0.28–3.01 | 0.88 | 0.76 | 0.23–2.50 | 0.66 | |
| Age | 1.81 | 0.89–3.67 | 0.10 | 1.04 | 0.99–1.08 | 0.09 | |
| Smoker | 0.66 | 0.31–1.40 | 0.27 | 0.86 | 0.41–1.80 | 0.69 | |
| Alcohol consumption | 0.90 | 0.44–1.83 | 0.76 | 1.14 | 0.57–2.26 | 0.71 | |
| Primary tumor | 0.96 | 0.76–1.20 | 0.70 | 0.93 | 0.75–1.15 | 0.48 | |
| Disease stage | 2.79 | 0.84–9.25 | 0.09 | 3.16 | 0.96–10.41 | 0.06 | |
| p16 status | 0.93 | 0.61–1.43 | 0.74 | 0.85 | 0.58–1.26 | 0.43 | |
| Comorbidity | 1.70 | 0.84–3.45 | 0.14 | 1.46 | 0.75–2.83 | 0.27 | |
| Cyfra21-1 | 4.12 | 1.92–8.87 | <0.001 | 3.23 | 1.63–6.41 | 0.001 | |
OS, overall survival; PFS, progression-free survival; OPSCC, oropharyngeal squamous cell carcinoma; CRT, concurrent chemoradiotherapy; Cyfra21-1, cytokeratin 19 soluble fragment.